MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic⦠read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
$1.24
Price-2.36%
-$0.03
$60.817m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$134.600k
-
1y CAGR-
3y CAGR-
5y CAGR-$11.812m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.24
-
1y CAGR-
3y CAGR-
5y CAGR$46.857m
$49.824m
Assets$2.967m
Liabilities$301.880k
Debt0.6%
-
Debt to EBITDA-$6.094b
-
1y CAGR-
3y CAGR-
5y CAGR